IP Verse

Curevac Se competitive analysis

Latest patents of Curevac Se opposed by its competitors

Explore Curevac Se's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 27, 2026
Patent NumberPublication DateTitleTotal Oppositions
EP4227319
Nov 26, 2025Novel Rsv Rna Molecules And Compositions For Vaccination1
EP4023755
Apr 26, 2023Artificial Nucleic Acid Molecules For Improved Protein Expression4
EP3708668
Jul 27, 2022Artificial Nucleic Acid Molecules For Improved Protein Expression4
EP3115064
Nov 24, 2021Rna-Coded Antibody1
EP3297682
Jul 14, 2021Dry Powder Composition Comprising Long-Chain Rna2
EP3298142
Jul 14, 2021Dry Powder Composition Comprising Long-Chain Rna2
EP3294326
Apr 21, 2021Prime-Boost Regimens Involving Administration Of At Least One Mrna Construct1
EP3062798
May 6, 2020Modified Rna With Decreased Immunostimulatory Properties2
EP3116535
Aug 7, 2019Combination Of Vaccination And Ox40 Agonists2
EP3173092
Jun 26, 2019Rna Containing Composition For Treatment Of Tumor Diseases5

Latest PTAB cases involving Curevac Se

Discover the latest PTAB cases involving Curevac Se, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Curevac Se with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
CUREVAC180 - 1
BIONTECH31101 -
ETHERNA IMMUNOTHERAPIES12 - - -
SANOFI7126 - -